INTRODUCTION
Autologous vascular tissue remains the gold standard conduit for small-diameter (<6 mm) vascular bypass. Many patients afflicted with peripheral arterial disease (PAD) lack suitable autologous tissue needed for bypass due to systemic disease or prior vein harvest [1] . The current alternative for these patients is bypass using a prosthetic graft or cryopreserved allograft, both of which produce inferior results [2, 3] . As a result of this problem, tissue engineering strategies have emerged in an attempt to create a more suitable alternative conduit. The ultimate goal is to create a graft composed of endothelial cells (EC) and smooth muscle cells (SMC) with structure and function similar to native vessels.
Many tissue engineering strategies for creating a bypass graft have used adult stem cells harvested from bone marrow or blood [4] [5] [6] [7] [8] . While both of these stem cell populations have shown potential to differentiate into mature cell lineages, cell harvest can be difficult, and availability of these cells is limited by advanced patient age and the presence of comorbidities [5] [6] [7] [8] [9] [10] . Adipose tissue has been shown to be an abundant source of stem cells that are easily obtainable [9, 11, 12] . Prior work in our laboratory has shown that adipose-derived stem cells (ASC) are able to differentiate into an endothelial cell lineage that can be seeded onto a bypass graft scaffold [9, 13] . One next step toward the production of a tissue engineered bypass conduit is to focus on ASC differentiation toward a SMC lineage.
Smooth muscle cells are defined by both molecular markers and function. There are five molecular markers commonly used in the literature to assess for SMCs. These markers are a-smooth muscle actin (ASMA), SM22, calponin, caldesmon, and myosin heavy chain (MHC). a-Smooth muscle actin and SM22 are early markers of developing smooth muscle. They are not specific to a smooth muscle cell lineage and have been shown to be transcribed in pluripotent stem cells. Calponin, caldesmon, and MHC are intermediate to late markers of SMC differentiation and are more specific to a SMC lineage. Smooth muscle cell function includes contraction and production of extracellular matrix. SMC differentiation has been described in the literature using many different adult stem cell sources, including bone marrow, adipose, and neural crest [14] [15] [16] [17] [18] . The majority of these studies have used soluble growth factors to induce differentiation. Factors, such as transforming growth factor b-1 (TGFb1) [14] [15] [16] 18] , transforming growth factor b-3 (TGFb3) [17] , angiotensin II (ANG) [18] , sphingosylphosphorylcholine (SPC) [17] , ascorbic acid [16] , and platelet-derived growth factor BB [15, 16] , have been used to induce varying degrees of SMC differentiation. Culture conditions differ across the studies, including the concentration of the growth factor and the type of media used. Different stock media are used with varying concentrations of glucose and fetal bovine serum (FBS). Occasionally, the media is enhanced with other supplements in addition to the differentiating agent being evaluated. Additionally, the various studies use different molecular markers to assess differentiation. This lack of consistency across studies makes it difficult to compare and interpret results.
The purpose of this study is to investigate the influence of certain soluble factors on SMC differentiation of ASC. By using a single stem cell type and consistent, standardized culture conditions, our goal is to compare the potential of the soluble factors ANG, SPC, and TGFb1 to drive ASC toward a SMC phenotype. The SMC phenotype will be assessed on a molecular level by the expression of calponin, caldesmon, and MHC, and functionally based on contractility. We will also explore the potential for use of these differentiated ASC in the creation of a tissue-engineered vascular bypass graft.
MATERIALS AND METHODS
The Thomas Jefferson University Institutional Review Board (IRB) approved of all human studies. All patients gave informed consent prior to tissue donation.
ASC Isolation
Human adipose tissue was collected from the peri-umbilical region of patients undergoing elective vascular surgical procedures via liposuction aspiration ( Table 1 ). The adipose tissue was digested in Collagenase I (4 mg/gm tissue; Worthington, Biochemical Corp., Lakewood, NJ) for 1 h at 37 C. Next, it was centrifuged at 1500 3 g to separate the cellular component. After discarding the supernatant, the resultant stromal-vascular pellet was suspended in non-differentiating media (Media-199; Mediatech, Herndon, VA) supplemented with 13% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), antibiotic-antimycotic solution (12 mL/L; Mediatech) and heparin (7.5 U/mL). Finally the stromal vascular fraction, containing our ASC population (CD13 þ 29 þ 90 þ ), was plated on gelatin-coated culture flasks (1 3 10 6 cells per flask) at 37 C in 5% CO 2 . Previous analysis has shown that greater than 98% of the cell population is CD13 þ 29 þ 90 þ , and that ASC cultures were morphologically homogeneous [13] .
Differentiation of ASC
ASC were differentiated toward a smooth muscle cell lineage via exposure to soluble factors. Differentiating media consisted of Media-199 (Mediatech), 13% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA), antibiotics (12 mL/L; Mediatech), heparin (7.5 U/mL), and one of the following supplements: (1) 1 mM angiotensin II (Sigma-Aldrich, St. Louis, MO), (2) 2 mM sphingosylphosphorylcholine (Matreya, LLC; Pleasant Gap, PA),or (3) 2 ng/mL TGF-b1 (R and D Systems, Inc., Minneapolis, MN) [17, 18] . ASC were cultured in differentiating media for up to 3 wk. Media was changed twice weekly throughout the culture period.
Cell Proliferation Assay and Doubling Time
Cell counts were performed every 24 h for 7 d using a Coulter counter (Beckman Coulter, Inc., Fullerton, CA) for ASC (n ¼ 3) grown in each of our four culture medias: non-differentiating media (no supplements added), ANG, SPC, and TGFb1. Starting cell counts were 2 3 10 4 for each cell population. Doubling time (T d ) was calculated using the following formula: T d ¼ (t 1 -t 0 )log2/log(N 1 /N 0 ) where t 1 is the time of the second cell count, t 0 is the time of the first cell count, N 1 is the number of cells in the second cell count, and N 0 is the number of cells in the first cell count.
Evaluation of Differentiation
Differentiation of ASC was evaluated by (1) expression of SMC markers, and (2) assessment of contractile function. Human arterial smooth muscle cells (American Type Culture Collection, Manassas, VA) were used as positive control and undifferentiated ASC were used as negative control.
Expression of SMC Specific Markers: RT-PCR
Expression of smooth muscle cell markers were identified by isolating total RNA from differentiated cells after 1 and 2 wk in culture. Total RNA was extracted through RNeasy mini columns (Qiagen, Valencia, CA). RNA concentration was obtained via spectrophotometer analysis. Reverse transcription was then performed by using the Promega reverse transcription system (Promega, Madison, WI). One mg of total RNA was used in each reaction. The following primer pairs (Operon, Huntsville, AL) were used: Calponin (forward 5 0 ATGTCCTCTGCTCA CTTCA3 0 ; reverse 5 0 TTTCCGCTCCTGCTTCTCT3 0 ), Caldesmon (forward 5 0 AGATTGAAAGGCGAAGAGCA3 0 ; reverse 5 0 TTCAAGCCAGC AGTTTCCTT3 0 ), MHC (forward 5 0 GGACGACCTGGTTGTTGATT3 0 ; reverse 5 0 GTAGCTGCTTGATGGCTTCC3 0 ). Gel electrophoresis was then performed on a 2% agarose gel treated with ethidium bromide and visualized using a UV light box.
Expression of SMC Specific Markers: Quantitative PCR
Total RNA was isolated from differentiated cells after 1 and 2 wk in culture using RNeasy Mini Kit (Qiagen) according to manufacturer's protocol. TaqMan gene expression assays targeting the smooth muscle cell markers calponin, caldesmon and MHC were obtained (Hs00154543_m1 CNN1, Hs00263989_m1 CALD1, Hs00224610_m1 MYH11; Applied Biosystems, Foster City, CA). Gene transcripts were measured by TaqMan real-time reverse transcription PCR with the 7500 Fast Real-Time PCR system (Applied Biosystems). Human GAPDH was used as internal control for standardization.
Expression of Cell Specific Markers: Western Blot
Total protein was extracted from differentiated cells using a sodium dodecyl sulfate derived buffer and quantified using BioRad protein assay kit (BioRad, Hercules, CA). Proteins were separated on a 4% to 12% graded tris-glycine gel (Invitrogen, Carlsbad, CA) and transferred to a polyvinylidene difluoride membrane (Invitrogen). Membranes were blocked with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE), then incubated overnight with primary antibody in Odyssey blocking buffer/0.1% Tween 20. The following primary antibodies were used: anti-calponin, anti-caldesmon, and anti-MHC (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Bound primary antibody was labeled with horseradish peroxidase (HRP)conjugated goat anti-mouse or goat anti-rabbit (Santa Cruz Biotechnology, Inc.). Signals were detected using the Odyssey imaging system (LI-COR Biosciences).
Assessment of Function: Collagen Gel Lattice Contraction Assay
In order to measure contractility, a collagen gel lattice contraction assay was performed [19] . Differentiated ASC were trypsinized from monolayer culture, counted, and resuspended in Media-199 at a density of 1 3 10 6 cells/mL. The collagen lattice was prepared by combining 270 uL of collagen solution (PurCol, Advanced BioMatrix, San Diego, CA), 15 uL sodium bicarbonate, and 30 uL of 10 3 Media-199. Two hundred mL of the cell solution were then added to the collagen lattice mixture. The cell-collagen mixture was pipetted into 24-well culture plates and incubated for 90 min at 37 C to polymerize the collagen cell lattices. After 90 min, the collagen lattices were mechanically released from the culture dish by pipetting either serumfree medium alone or serum-free medium containing 60 mM KCl at the lattice-dish interface. Serum-free medium alone was used to determine basal contractile tone of the cells, while the addition of KCl was to assess a stimulated contractile response as a result of membrane depolarization. A digital camera at a fixed distance was used to take pictures of the lattices at specific time points after release. The area of the gel lattice was calculated using NIH Image J software (NIH, Bethesda, MD). The relative amount of contraction was obtained using the following formula: relative gel area ¼ gel surface area at specific time point/initial gel surface area. Percent increase in contraction was calculated using the following formula: relative gel area of cells in serum-free medium containing KCl -relative gel area of cells in serum-free medium alone.
Attachment to Vascular Graft Scaffold
Human greater saphenous vein (Regeneration Technologies Inc., Birmingham, AL) was decellularized by placing the specimen in a 0.075% SDS (Sigma Chemical Co., St. Louis, MO) solution in a 37 C shaking water bath for 15 h. The vein was then washed with agitation in phosphate-buffered saline five times. Differentiated ASCs were trypsinized from monolayer culture, counted and resuspended in DMEM at a concentration of 1 3 10 7 cells/mL. Fifty mL of cell suspension was applied to the abluminal surface of the decellularized vein and allowed to incubate at 37 C for 1 h. The vein was flipped over and an additional 50 mL of cell suspension was applied to the other side of the vein and allowed to incubate for 1 h. At this time, the seeded decellularized vein was placed onto a bioreactor system (Tissue Growth Technologies, Minnetonka, MN) and DMEM media was circulated around the abluminal surface of the vein. After 24 h, the vein was harvested from the bioreactor system and the abluminal surface was stained with 2 mL of Cell Tracker Green (Invitrogen, Carlsbad, CA). Cell attachment was assessed using confocal microscopy at 3 40 magnification.
Statistical Analysis
All values are expressed as mean 6 standard deviation. Statistical analysis was performed on quantified data (qPCR and contraction assay) using a two-tailed Student's t-test. P value <0.05 was considered significant.
RESULTS

Proliferation Characteristics
Undifferentiated ASC showed similar proliferation compared with ASC grown in media supplemented with ANG, SPC or TGFb1 (Fig. 1) . The doubling times for each of the four culture conditions between 0 and 7 d were: undifferentiated ASC 2.9 6 0.2 d, ANG There were no significant differences among these four groups with regard to doubling times.
Effect of ANG, SPC, and TGFb1 on the Expression of SMC Markers
Prior to culture with the three differentiating agents, ASC did not express calponin or MHC, however, expression of caldesmon was seen in two of four patient cell lines as evidenced by RT-PCR (Fig. 2) . After 1 wk in culture, expression of calponin was seen after differentiation with all three agents in one cell line only. All other cell lines did not express calponin. Expression of caldesmon was variable among cell lines. Two cell lines did not show up-regulation of caldesmon, one showed up-regulation with all three agents, and another showed up-regulation with ANG only. No MHC expression was seen with any cell lines at 1 wk.
After 2 wk of differentiation, up-regulation of calponin expression was seen with TGFb1 in one cell line only by RT-PCR ( Fig. 3 ). All others did not show up-regulation of calponin. At 2 wk, expression of caldesmon was slightly variable with only half of the cell lines showing up-regulation of caldesmon. Expression of MHC was seen with TGFb1 in three cell lines and with SPC in another cell line at 2 wk, while two cell lines did not show any MHC expression.
When SMC marker expression was quantified using quantitative PCR (Fig. 4) , results remained variable across the different cell lines. Up-regulation of calponin was seen with TGFb1. No up-regulation of caldesmon was achieved by any of the stimulating agents. Some up-regulation of MHC was seen with ANG and SPC. However, no consistent pattern of expression was observed across all cell lines for any of the SMC markers.
Western blot analysis after 3 wk in culture ( Fig. 5 ) revealed up-regulation of calponin protein with all three agents in two of three cell lines. A third cell line showed up-regulation of calponin protein with TGFb1 only. No up-regulation of caldesmon protein was observed with any of the agents, although caldesmon protein was expressed at baseline and with all agents. No expression of MHC protein was seen.
Assessment of Function: Collagen Gel Lattice Contraction Assay
Unseeded collagen gels maintain their surface area over time, therefore, any change in surface area is due to contraction from cells seeded within the gel (Fig. 6 ). Basal contractile tone is exhibited by undifferentiated ASC and stem cells differentiated with each of the three agents. The amount of basal tone is less than the amount exhibited by the positive control (human arterial SMCs). The addition of KCl results in a significant increase in contraction with ASC differentiated with SPC and TGFb1 compared with undifferentiated ASC, similar to the positive control. No increase in contraction was seen with ASC differentiated in ANG.
Attachment to Vascular Graft Scaffold
ASC differentiated in either ANG, SPC, or TGFb1 attach to abluminal surface of decellularized human greater saphenous vein after 24 h in bioreactor system as viewed by confocal microscopy (Fig. 7) . Cells remain attached to vein and viable as long as 1 wk in the bioreactor system.
DISCUSSION
In the present study we evaluated the effect of three growth factors (ANG, SPC, and TGFb1) on differentiation of human adipose-derived stem cells toward a SMC lineage and the potential use of the differentiated cells in the creation of a tissue engineered vascular bypass graft. We observed considerable variation in expression of the SMC markers calponin, caldesmon, and MHC at both the gene and protein levels with all three growth factors across different cell lines. Assessment of functionality revealed that ASC differentiated in SPC and TGFb1 showed contraction in response to stimulation by KCl, a characteristic of differentiated SMCs. Stem cells differentiated in either ANG, SPC, or TGFB were able to be seeded successfully onto a decellularized vascular graft.
To date, only two other laboratories have published data on the differentiation of human ASCs into SMCs [17, 18, 20] [20] . They demonstrated up-regulation of the markers ASMA, calponin, caldesmon, SM22, smoothelin, and MHC by RT-PCR and up-regulation of ASMA and MHC by Western blot analysis. In our study, cells were cultured in media comprised of Medium 199, 10% fetal bovine serum, penicillin/streptomycin, and the addition of either ANG, SPC, TGFb1, or no growth factors. Due to difference in culture media, we are not able to support or refute their claim. However, we did not achieve the same up-regulation of markers calponin, caldesmon, and MHC reported in this study.
In contrast, a second set of collaborators reported that ANG, SPC, TGFb1, and TGFb3 added to culture media comprised of a-minimum essential medium with 10% fetal bovine serum and penicillin/streptomycin, all induced SMC differentiation by human ASCs [17, 18] . Jeon et al. reported up-regulation of the markers ASMA, calponin, and SM22 by SPC and TGFb3 as evidenced by RT-PCR and qPCR, and up-regulation of ASMA by SPC, TGFb1, and TGFb3 on Western blot analysis [17] . Both ASMA and SM22 are early markers of developing smooth muscle. They are not specific to a SMC lineage and have been shown to be spontaneously expressed in pluripotent stem cells. We found both ASMA and SM22 to be transcribed in our native ASC population on RT-PCR analysis (data not shown); therefore, we did not use these markers in our evaluation of differentiation. Our RT-PCR and qPCR analysis did not show consistent up-regulation of calponin by SPC across all cell lines. Therefore, we cannot support their claim that SPC induces SMC differentiation in human ASCs.
In a second publication, this same lab reported upregulation of ASMA, calponin, caldesmon, and MHC by both ANG and TGFb1 on Western blot analysis [18] . Our Western blot analysis of differentiation demonstrated up-regulation of calponin by ANG in two of three cell lines and by TGFb1 in all three cell lines. We did not observe any up-regulation of caldesmon or MHC by either ANG or TGFb1. Based on these results, we agree that ANG and TGFb1 drive ASCs toward a SMC lineage based on expression of calponin, but cannot say that it induces a fully differentiated state due to lack of MHC expression. The present study showed that neither ANG, SPC, nor TGFb1 were able to induce adipose-derived stem cells to a fully differentiated SMC phenotype based on the expression of molecular markers, however, all three agents do drive SMC differentiation in adipose-derived stem cells to some degree. In addition to molecular markers, we also studied our differentiated stem cells to see if they acquired the contractile function of smooth muscle. We found that ASCs differentiated in SPC and TGFb1 expressed basal contractile tone and demonstrated a significant increase in contraction in response to stimulation with KCl, both characteristics of smooth muscle. Contractile response to KCl was not observed in ASC differentiated in ANG. This contractile function of differentiated ASC has important implications for vascular tissue engineering. Contractility adds functional properties to a vascular graft that are similar to native arteries. It provides added strength to the graft, thereby increasing the ability of the graft to withstand physiologic stresses [21] . This results in a graft with sufficient strength not to burst with changes in blood pressure. The addition of contractile function creates a vasoreactive graft that is able to alter its diameter and compliance in response to hemodynamic forces and chemical stimuli. Thus, the contractile function of differentiated ASC is important in creating a functional vascular conduit that possesses the mechanical properties of a native blood vessel.
Smooth muscle cells are important in the creation of tissue-engineered blood vessels. They provide increased strength to vessels when circumferentially oriented, creating a graft that can withstand cyclic loading and is able to handle changes in arterial blood pressure without rupture [22, 23] . The contractile function of SMCs creates a graft that is vasoreactive to external stimuli. This allows propagation of pulsatile flow and physiologic adjustments in flow based on cardiovascular demand. The synthetic function of SMCs results in production of extracellular matrix (ECM) comprised of collagen, elastin, and proteoglycans, which allows for elasticity and improved compliance of the graft. For these reasons, SMCs are an integral part in constructing a bypass graft. Several tissue-engineered grafts using SMCs have been constructed. Ratcliffe created a graft consisting of a polyurethane scaffold seeded with SMCs and ECs cultured under fluid flow [24] . When implanted into canine carotid arteries, the grafts remained patent and free from intimal hyperplasia for 4 wk. Shum-Tim et al. seeded polyglycolic acid (PGA)polyhydroxyalkanoate (PHA) co-polymer scaffolds with ovine carotid ECs and SMCs [25] . When implanted in the infrarenal aortas of lambs, the grafts remained patent for 5 mo, and over time showed collagen content and mechanical stress curves similar to those of native aorta. Niklason et al. seeded bovine aortic SMCs and ECs onto a PGA scaffold placed around a distensible silicon tube in a biomimetic system [26] . When the silicon tube was removed, the resultant graft had collagen content and wall thickness comparable to native arteries, and burst strength greater than that reported for native human greater saphenous veins. Niklason et al. also described the use of bone marrow-derived stem cells in the creation of a tissue-engineered graft [27] . They seeded a PGA scaffold with stem cells in a biomimetic system for 8 wk under conditions for stem cell proliferation and differentiation. The result was a graft containing stem cells differentiated toward a SMC lineage, and increased collagen and extracellular matrix content. In this study, we have shown that adipose-derived stem cells differentiated toward a SMC lineage by ANG, SPC, or TGFb1 are able to attach to a vascular graft scaffold (decellularized saphenous vein). Thus, adipose-derived stem cells have the potential for use in the creation of tissue engineered blood vessels.
The main weakness of our current study is the variability of SMC marker expression experienced across different cell lines. Consistent expression of various SMC markers has been reported using stem cells from a variety of sources. One explanation for our variability in expression could be due to loss of differentiation potential by the adipose-derived stem cells that is not seen in other cell lines. As discussed above, others have reported consistent expression of SMC markers using adiposederived stem cells, however, this was not our experience [17, 18, 20] . It is also possible that the variability in expression is due to differences between our study and others in the patient population from which our adipose samples were obtained. Our samples were harvested from older patients (mean age 65 y), the majority of whom had one or more comorbid conditions ( Table 1) . The other studies using ASC for SMC differentiation do not describe their patient population [17, 18, 20] . Perhaps these patient populations consist of younger patients, fewer comorbidities, or other differences that may have resulted in less variability. Another reason for variable SMC marker expression could be from poor stimulation of differentiation. This seems less likely since the agents used have been previously reported to induce differentiation at similar concentrations.
In summary, these data suggest that human adiposederived stem cells (1) exhibit variable expression of SMC molecular markers after differentiation, (2) exhibit a contractile phenotype after differentiation with SPC and TGFb1, and (3) can attach to a vascular graft scaffold. Thus, adipose-derived stem cells can be driven toward a SMC lineage, and have potential for use in the construction of autologous arteries.
